Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma-Reference-Cited by-同舟云学术

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

Published:2019-07-12 Issue:9 Volume:134 Page:761-764
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:Blood

Author:

Freeman Ciara L.^ORCID,Kridel Robert^ORCID,Moccia Alden A.,Savage Kerry J.,Villa Diego R.^ORCID,Scott David W.,Gerrie Alina S.^ORCID,Ferguson David,Cafferty Fergus,Slack Graham W.,Farinha Pedro^ORCID,Skinnider Brian,Connors Joseph M.,Sehn Laurie H.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference18 articles.

1. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

3. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

4. Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM Study;Launonen;Blood,2017

5. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression;Seymour;Haematologica,2018

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era;Bone Marrow Transplantation;2024-08-20

3. Identification of genetic subtypes in follicular lymphoma;Blood Cancer Journal;2024-08-07

4. Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma;Pharmacoepidemiology;2024-08-06

5. Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2024-08